| Title |
Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, July 2015
|
| DOI | 10.1007/s10555-015-9572-2 |
| Pubmed ID | |
| Authors |
Seyed Fazel Nabavi, Stefania Bilotto, Gian Luigi Russo, Ilkay Erdogan Orhan, Solomon Habtemariam, Maria Daglia, Kasi Pandima Devi, Monica Rosa Loizzo, Rosa Tundis, Seyed Mohammad Nabavi |
| Abstract |
Over the past decades, extensive studies have addressed the therapeutic effects of omega-3 polyunsaturated fatty acids (omega-3 FAs) against different human diseases such as cardiovascular and neurodegenerative diseases, cancer, etc. A growing body of scientific research shows the pharmacokinetic information and safety of these natural occurring substances. Moreover, during recent years, a plethora of studies has demonstrated that omega-3 FAs possess therapeutic role against certain types of cancer. It is also known that omega-3 FAs can improve efficacy and tolerability of chemotherapy. Previous reports showed that suppression of nuclear factor-κB, activation of AMPK/SIRT1, modulation of cyclooxygenase (COX) activity, and up-regulation of novel anti-inflammatory lipid mediators such as protectins, maresins, and resolvins, are the main mechanisms of antineoplastic effect of omega-3 FAs. In this review, we have collected the available clinical data on the therapeutic role of omega-3 FAs against breast cancer, colorectal cancer, leukemia, gastric cancer, pancreatic cancer, esophageal cancer, prostate cancer, lung cancer, head and neck cancer, as well as cancer cachexia. We also discussed the chemistry, dietary source, and bioavailability of omega-3 FAs, and the potential molecular mechanisms of anticancer and adverse effects. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 257 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 255 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 40 | 16% |
| Student > Bachelor | 29 | 11% |
| Researcher | 26 | 10% |
| Student > Doctoral Student | 19 | 7% |
| Student > Ph. D. Student | 18 | 7% |
| Other | 59 | 23% |
| Unknown | 66 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 21% |
| Agricultural and Biological Sciences | 31 | 12% |
| Biochemistry, Genetics and Molecular Biology | 26 | 10% |
| Nursing and Health Professions | 18 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 4% |
| Other | 26 | 10% |
| Unknown | 90 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2021.
All research outputs
#14,825,310
of 22,828,180 outputs
Outputs from Cancer and Metastasis Reviews
#595
of 808 outputs
Outputs of similar age
#144,446
of 262,905 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#9
of 13 outputs
Altmetric has tracked 22,828,180 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 808 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,905 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.